Deep brain stimulation response in obsessive–compulsive disorder is associated with preoperative nucleus accumbens volume

Luka C. Liebrand a,b,1, Paul Zhutovsky a,1, Eva K. Tolmeijer c, Ilse Graat a, Nienke Vulink a, Pelle de Koning a, Martijn Fige e b,d, P. Richard Schuurman a, Pepijn van den Munckhof b, Matth an W.A. Caan b, Damiaan Denys a,f, Guido A. van Wingen a,*

a Department of Psychiatry, Amsterdam UMC, University of Amsterdam, Amsterdam Neuroscience, Amsterdam, the Netherlands
b Department of Biomedical Engineering and Physics, Amsterdam UMC, University of Amsterdam, the Netherlands
c Department of Clinical Psychology, VU University, Amsterdam Public Health Research, Amsterdam, the Netherlands
d Icahn School of Medicine at Mount Sinai, New York, NY, United States
e Department of Neurosurgery, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands
f Netherlands Institute for Neuroscience, Royal Academy of Arts and Sciences, Amsterdam, the Netherlands

ARTICLE INFO
Keywords:
Deep brain stimulation
Obsessive–compulsive disorder
Nucleus accumbens
Anterior limb of the internal capsule
Treatment outcome prediction
Machine learning

ABSTRACT
Background: Deep brain stimulation (DBS) is a new treatment option for patients with therapy-resistant obsessive–compulsive disorder (OCD). Approximately 60% of patients benefit from DBS, which might be improved if a biomarker could identify patients who are likely to respond. Therefore, we evaluated the use of preoperative structural magnetic resonance imaging (MRI) in predicting treatment outcome for OCD patients on the group- and individual-level.

Methods: In this retrospective study, we analyzed preoperative MRI data of a large cohort of patients who received DBS for OCD (n = 57). We used voxel-based morphometry to investigate whether grey matter (GM) or white matter (WM) volume surrounding the DBS electrode (nucleus accumbens (NAc), anterior thalamic radiation), and whole-brain GM/WM volume were associated with OCD severity and response status at 12-month follow-up. In addition, we performed machine learning analyses to predict treatment outcome at an individual-level and evaluated its performance using cross-validation.

Results: Larger preoperative left NAc volume was associated with lower OCD severity at 12-month follow-up (p FWE < 0.05). None of the individual-level regression/classification analyses exceeded chance-level performance.

Conclusions: These results provide evidence that patients with larger NAc volumes show a better response to DBS, indicating that DBS success is partly determined by individual differences in brain anatomy. However, the results also indicate that structural MRI data alone does not provide sufficient information to guide clinical decision making at an individual level yet.

1. Introduction

Deep brain stimulation (DBS) is a new treatment option for approximately 10% of patients with obsessive–compulsive disorder (OCD) who do not benefit from conventional pharmacological and psychological therapies (Denys et al., 2020). On average, around 60% of these treatment-resistant patients respond to DBS (Alonso et al., 2015). Clinical predictors for DBS outcomes in OCD are scarce, with, e.g., an older age at onset of OCD being associated with better response on the group level (Alonso et al., 2015). However, these predictors cannot yet be used to determine which individual patients may or may not be suitable for DBS. While recent studies showed that treatment response might improve with diffusion magnetic resonance imaging (MRI) guided DBS targeting (Baldermann et al., 2019; Coenen et al., 2017; Liebrand et al., 2019), it is unlikely that all patients will become responders in the future. Since OCD has been associated with various structural brain

* Corresponding author at: Department of Psychiatry, Amsterdam UMC – location AMC, Meibergdreef 9, 1105AZ Amsterdam, the Netherlands.
E-mail address: G.A.vanWingen@amsterdamumc.nl (G.A. van Wingen).
1 Both authors contributed equally to this work.

https://doi.org/10.1016/j.nicl.2021.102640
Received 10 November 2020; Received in revised form 16 March 2021; Accepted 17 March 2021
Available online 22 March 2021
2213-1582/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
abnormalities (Boedho et al., 2017; Gan et al., 2017; Hashimoto et al., 2014), differences in (individual) brain structure might be used to predict treatment response. Multiple studies used structural MRI data to predict treatment outcome in OCD (e.g., (Hashimoto et al., 2014; Yun et al., 2015)), but few studies examined neural biomarkers for treatment-resistant OCD (Dunlop et al., 2016; Van Laere et al., 2006). Nevertheless, the potential benefits of a reliable biomarker for DBS response are substantial. First, DBS is a long-term invasive treatment which carries several risks (Alonso et al., 2015; de Koning et al., 2011) and presents a possible burden to the patient, which could be avoided if potential non-responders are identified early. Second, DBS is a costly treatment with limited availability. Selecting only those patients who are likely to benefit would increase DBS’s cost-effectiveness, since the likelihood of DBS being cost-effective is only 57% over the first two years (Ooms et al., 2017). This could increase the availability of DBS, speeding up patients’ and referring clinicians’ decision to start treatment. In addition, an effective biomarker could provide valuable information regarding the pathophysiology of (treatment-resistant) OCD.

The nucleus accumbens (NAc) and the neighboring ventral capsule have been the most popular DBS targets for OCD (Abbas et al., 2015). These targets, which were adapted from white matter lesioning sites (Tierney et al., 2014), form a central hub within the cortico-striatal-thalamic-cortical (CSTC) loop (Wood and Ahmari, 2015). Previous findings suggest that DBS reduces OCD symptoms by disrupting pathological hyperconnectivity within the CSTC circuitry (Fige et al., 2013; Schmuckermair et al., 2013), preventing neurons in frontostriatal networks to synchronize (Bahramisharif et al., 2016; Smolders et al., 2013). The NAc is assumed to play an important role in integrating inputs within the CSTC circuitry, receiving dopaminergic and glutamatergic inputs from the ventral tegmental area and cortico-limbic regions, respectively (Wood and Ahmari, 2015). Successful DBS renormalizes abnormal striatal dopamine levels in OCD patients (Fige et al., 2014), which is in agreement with the assumed working mechanism of the same DBS target for depression (Coenen et al., 2011). Recent tractography studies further support the idea that connections to distal brain regions are important in DBS treatment response, even suggesting that white matter tracts running through the ventral capsule may be the optimal targets. Specifically, these studies have pointed towards the suprolateral medial forebrain bundle (sMFB) (Coenen et al., 2018; Liebrand et al., 2019), possibly in combination with frontothalamic fibers (likely part of the anterior thalamic radiation (ATR)) (Baldermann et al., 2019). Complementary to their importance as targets, the NAc, sMFB and ATR might contain crucial information regarding treatment response.

In this retrospective study, we perform group- and individual-level analyses on preoperative structural MRI data to infer a potential relationship between voxel-wise grey- and white-matter volume (GM/WM) and DBS treatment response using one of the largest cohorts of OCD patients who received DBS to date. We hypothesized that grey matter (NAc) and white matter (ATR and sMFB) volume surrounding the DBS electrodes would be suitable for predicting improvement in OCD symptoms following DBS treatment. More exploratory, we also investigated DBS treatment effects on the whole-brain level.

2. Material and methods

2.1. Patients

We retrospectively retrieved and analyzed all available anonymized data of patients who received DBS for treatment-refractory OCD at the Amsterdam UMC (location AMC) in Amsterdam, The Netherlands, between 2005 and 2017. The first 16 patients participated in a clinical trial (Denys et al., 2010), while all consecutive patients received DBS as part of routine healthcare (Denys et al., 2020). We automatically retrieved preoperative MRI data of 63 patients. Data of six patients were excluded during preprocessing due to suboptimal segmentation or image artifacts (details in the Imaging section), so that datasets from 57 patients were used for the final analyses.

Patients aged 18–65 were eligible for treatment if they had a primary diagnosis of severe treatment-resistant OCD according to the DSM-IV (American Psychiatric Association, 2000) for over 5 years, with a minimum symptom score of 28 on the Yale-Brown obsessive compulsive scale (Y-BOCS). Patients were eligible for DBS if they did not previously respond to two 12-week trials with a selective serotonin reuptake inhibitors (SSRI) at maximum dosage, including augmentation with an atypical antipsychotic for 8 weeks, one 12-week trial of the maximum dosage olanzapine and cognitive behavioral therapy (CBT) at a center specialized in OCD (Denys et al., 2020). Contraindications for DBS were presence of psychotic disorders, recent substance abuse, and unstable neurological or coagulation disorders. Severe comorbid DSM diagnoses such as bipolar disorder or autism spectrum disorder were relative contraindications, outside of the first 16 patients included in our trial for whom these were always exclusion criteria. An independent psychiatrist monitored the inclusion process. More details about the included patients and inclusion and exclusion criteria can be found in (Denys et al., 2020).

Since this is a retrospective study with anonymized datasets that does not burden the patient, according to the Dutch Medical Research Involving Human Subjects Act (WMO) this study did not require approval from a medical-ethical committee. The institutional review board of Amsterdam UMC waived the obligation to obtain informed consent.

2.2. Treatment

2.2.1. DBS lead implantation

Patients were bilaterally implanted under general anesthesia, according to standard stereotactic procedures. Surgical planning was performed based on anatomical landmarks in SurgiPlan (Elekta AB, Stockholm, Sweden), such that the active DBS contacts (model 3389, Medtronic, Minneapolis, US; 4x 1.5 mm contacts with 0.5 mm interspace) were placed in the ventral anterior limb of the internal capsule (ALIC) (van den Munckhof et al., 2013). The electrodes were coronally angled to follow the ALIC trajectory with an approximate anterior angle of 75°. Correct lead placement was ensured with co-registration of postoperative computed tomography (CT) to preoperative structural MRI.

2.2.2. DBS optimization and CBT

The DBS device was switched on two weeks after surgery, marking the start of the optimization phase. In this phase, stimulation voltage, pulse duration and active contacts were subsequently updated in absence of clinical response. The clinical effect and tolerability of (side) effects of each new parameter combination was evaluated every two weeks, according to published protocols (van Westen et al., 2021). The aim of DBS optimization was to find a clinically effective and tolerable parameter combination. Once achieved, these parameters were kept stable. The length of the optimization phase was not uniform, since the time to find the optimal stimulation parameters varied between patients. At the end of the optimization phase, patients received CBT during which they had to challenge their symptomatic behavior to augment the clinical effect of DBS (Mantione et al., 2014).

2.2.3. Treatment outcome

Symptom severity was regularly assessed using the Y-BOCS, with a ≥35% symptom reduction with respect to the preoperative baseline determining treatment response. We computed DBS treatment response from baseline and 12-month follow-up Y-BOCS scores, which - outside of the first 16 patients - were obtained as part of routine clinical practice. In our analyses we first focused on the treatment response criterion as it has been used as a typical criterion of treatment success in DBS stimulation (Alonso et al., 2015). In addition, we also predicted the Y-BOCS score at 12-month follow-up directly as this approach should allow for better
statistical modelling than prediction of (binarized) percentage change (Altman and Royston, 2006).

2.3. Imaging

2.3.1. Data acquisition

The T1-weighted MRI data used in this study were all acquired for surgical planning according to clinical protocol. Given the large time-frame in which patients received DBS, different combinations of scanners/parameters were used in this study (Table S1).

2.3.2. MRI preprocessing

Preoperative MRI data was preprocessed using the standardized pipeline of the CAT12 toolbox (r1450, http://www.neuro.uni-jena.de/cat) for SPM12 (v7487, https://www.fil.ion.ucl.ac.uk/spm/software/spm12) in the MATLAB programming language (R2018b, The Mathworks, Natick, MA). Preprocessing included in-homogeneity correction, partial volume based segmentation and spatial normalization to MNI space via Geodesic Shooting normalization (Ashburner and Friston, 2011) utilizing a template derived from 555 subjects of the IXI-database (http://brain-development.org/) provided by the CAT12 toolbox. The final GM/WM segmentations were modulated by the Jacobian determinant accounting for volume changes during the normalization process. The quality of the segmentations was investigated through the quality control options provided by the CAT12 toolbox and visual inspection. This led to the exclusion of five patients due to suboptimal segmentation quality and one patient due to an artifact in the original MRI scan. Finally, data were spatially smoothed with an 8 mm full-width-at-half-maximum kernel.

For the analyses whole-brain GM and WM masks were created by thresholding individual GM/WM images at 0.15 and only including voxels which survived thresholding across all patients. Bilateral ROI-specific masks for the NAc and the ATR were extracted from the subcortical Harvard-Oxford atlas (25% threshold of the maximum probability maps) and the JHU white-matter tractography atlas (25% threshold of the maximum probability maps), respectively, which are both included in the FSL library (Jenkinson et al., 2012). It is important to note that a large part of the sMFB is included in the atlas definition of the ATR.

We also calculated scalar momenta (Ashburner and Klöppel, 2011) as an additional and more advanced form of MRI data representation since a recent benchmarking study showed them to provide increased performance in pattern recognition tasks (Monté-Rubio et al., 2018). Details on their computation can be found in the Supplementary Methods.

2.4. Statistical analyses

2.4.1. Clinical and demographic data

We summarized clinical and demographic data of the entire sample. To investigate whether responders and non-responders differed on demographic variables at baseline and follow-up (symptom severity) we applied label permutation tests (n = 1000) (Ojala and Garriga, 2010) to statistically determine whether the obtained performances (AUC for classification and MAE for regression) differed from chance-level at α = 0.05 Bonferroni-corrected for three tests corresponding to the different volumes per data scale (whole-brain or ROI). We corrected for three tests here because the individual-level analyses also considered the combination of each of our data representations (e.g., GM alone, WM alone and a combination of both GM + WM), contrary to the approach on the group-level.

We removed nuisance effects associated with age, sex, TIV, and scanner IDs via linear regression from the MRI data. Importantly, the estimation of the linear regression coefficients was always limited to the training set. In addition, baseline Y-BOCS score was added as a feature in both analyses. Given the high number of voxels in our dataset we implemented a feature selection approach. This corresponded to calculating Fisher scores (Li et al., 2017) in the classification case and Pearson correlations between each voxel and the Y-BOCS follow-up score across patients in the regression case. These calculations were again only performed on the training set. To determine the optimal percentage of features to select, a nested cross-validation procedure (with 5-fold CV as the inner CV) was implemented. All analyses were run for whole-brain GM/WM and NAc/ATR ROIs and the combination of GM/WM and NAc/ATR data. The combination corresponded to just concatenating the different feature maps. In addition, we also repeated the analysis for scalar momenta as a more advanced form of data representation. All analyses were implemented in the Python programming language (3.7.6) utilizing the scikit-learn toolbox (0.22.1, (Pedregosa et al., 2011)).

3. Results

3.1. Clinical and Demographic Data

A summary of the clinical and demographic data and statistical tests between responders and non-responders are reported in Table 1. Responders and non-responders did not statistically differ at baseline; only Y-BOCS scores at 12-month follow-up differed significantly between...
4. **Discussion**

The aim of this study was to investigate the relationship between voxel-wise brain volumetry and DBS treatment response in OCD. We related the 12-month follow-up Y-BOCS score to volumetric differences on the group-level, and tested whether brain volumes were predictive of outcomes on an individual-level with SVC/SVR. In our sample we found that larger preoperative volumes of the left NAc were significantly associated with lower Y-BOCS scores at 12-month follow-up. However, our machine learning analyses did not generate models that could predict individual-level outcome above chance-level.

The NAc is involved in the pathophysiology of OCD and is centrally located in the CSTC circuitry. For this reason the NAc was our original focus. The results of the group-level analyses are summarized in Fig. 1 and Fig. 2. We found a significant association between Y-BOCS scores at 12-month follow-up and left NAc grey-matter volume (31 voxels, maximum: 7.5, 15, −7.5 [mm], TFCE-value: 85.91) (Fig. 1). Lower follow-up Y-BOCS scores were associated with larger preoperative grey-matter volume (Fig. 2). This result remained significant when an additional covariate encoding time since first DBS operation (mean-centered) performed in the patient sample was added to the model. We did not find significant associations between clinical outcomes and volumes of the right NAc or ATR. However, right NAc grey-matter volume did show a comparable association at the uncorrected level, implying a potential lack of power to detect an effect. When comparing groups, larger NAc grey-matter volume in the same voxels was trend-level significant for responders over non-responders. There were no significant associations in the exploratory whole-brain analyses.

3.3. **MRI Individual-level analyses**

Results of individual-level regression and classification analyses are reported in Tables 2 and 3. None of the MRI data representations exceeded chance-level performance neither for the regression nor the classification analysis, neither when using whole-brain or ROI data.
stimulation to white matter bundles in the vALIC (Baldermann et al., 2019; Liebrand et al., 2019). It is possible that larger NAc volumes led to electrode positioning such that stimulation was closer to the relevant white matter structures. In this case, larger NAc volumes would rather reflect better odds of achieving optimal electrode positioning than directly predict response. Given the respective scales of the white matter variability in the vALIC (Liebrand et al., 2019) and NAc volumetric differences, the chance that these relatively small volumetric differences were responsible for a difference in electrode positioning large enough to affect treatment outcome appears small. Conversely, the surgical methods are unlikely to have played a role in the observed asymmetry. Although the left-sided electrode was usually implanted first, followed by the right-sided electrode since the infra-clavicular stimulator is usually implanted on the right side, the time between the two electrode insertions is short. Measures like glue in the burr-holes prevent the leakage of cerebrospinal fluid and intraoperative brain shift hardly occurs any longer so there is no asymmetry to be expected in the potential targeting inaccuracy.

Research into the role of the NAc in the context of predicting treatment outcome has been scarce, but earlier studies have linked the NAc to pharmacotherapy and psychotherapy resistance. Treatment-resistant OCD patients showed hypo-responsivity of the NAc during the anticipation of rewards (Figee et al., 2011), as well as micro-structural alterations of the NAc as measured with diffusion tensor fractional anisotropy (Li et al., 2014). More recently, a study investigating patients who received treatment with CBT and SSRIs for anxiety disorders found that larger baseline NAc volumes were associated with a larger reduction of anxiety symptoms (Burkhouse et al., 2020). The authors suggested that treatments targeting anxiety-related avoidance behavior were more effective in patients with larger pretreatment deficits in the systems responsible for the avoidance behavior, which was supported by studies showing a relationship between larger baseline NAc volume and

|       | AUC | Accuracy [%] | Sensitivity [%] | Specificity [%] |
|-------|-----|--------------|-----------------|-----------------|
| GM    | 0.468 (0.124) [0.167-0.694] | 48.21 (10.25) [26.67-72.86] | 56.76 (19.96) [16.67-100] | 39.67 (19.57) [0-80] |
| WM    | 0.422 (0.173) [0.0-0.80] | 44.90 (14.52) [16.67-72.86] | 57.52 (23.27) [0-100] | 32.27 (21.58) [0-60] |
| GM + WM | 0.433 (0.171) [0.0-0.833] | 48.10 (15.56) [0-80.00] | 60.67 (22.71) [0-100] | 35.53 (19.40) [0-66.67] |
| NAc   | 0.543 (0.213) [0.067-0.933] | 57.30 (13.23) [16.67-83.33] | 62.19 (19.62) [16.67-100] | 43.00 (22.41) [0-80] |
| ATR   | 0.509 (0.201) [0.10-0.933] | 42.86 (14.86) [16.67-73.33] | 47.19 (19.16) [0-85.71] | 38.53 (24.02) [0-100] |
| NAc + ATR | 0.481 (0.162) [0.133-0.767] | 48.57 (14.57) [16.67-75.71] | 54.14 (17.65) [16.67-85.71] | 43.00 (22.41) [0-80] |
| Scalar Momentum | 0.546 (0.136) [0.233-0.857] | 51.52 (10.24) [33.33-75.71] | 56.38 (17.21) [16.67-85.71] | 46.67 (18.52) [0-100] |

AUC: Area-under-receiver-operator-curve; GM: Grey-matter volume; WM: White-matter volume; NAc: Grey-matter volume of Nucleus Accumbens; ATR: White-matter volume of Anterior Thalamic Radiation.
more severe anxiety symptoms (Günther et al., 2018; Kühn et al., 2011) as well as between NAc structural alterations and avoidance behaviors in patients with anxiety symptoms (Lago et al., 2017). In our experience, the treatment effect in DBS for OCD is achieved by an initial anxiolytic effect that is further augmented by exposure-based CBT (Denys et al., 2010; Mantione et al., 2014). Taken together, the larger reduction of OCD symptoms in patients with larger NAc volumes may result from a larger effect of DBS on avoidance behaviors, which needs to be tested in future research. Patients with smaller NAc volumes might benefit less from treatment because the NAc’s ability to integrate dopaminergic inputs during reward processing may be impaired, which could interfere with resumption of normal functioning within the CSTC circuitry.

While an association between the left NAc volume and follow-up Y-BOCS was found on the group-level, both the SVC/SVR approaches did not yield predictive values significantly above chance-level. One possible explanation is that multivariate analyses typically require larger samples than univariate analyses (Bzdok and Ioannidis, 2019). Our sample, while sizable for psychiatric DBS studies, may not have been large enough to detect the complex patterns needed for individual-level prediction. Given the group-level association between NAc volume and Y-BOCS follow-up score, it is possible that future studies with larger sample sizes may be able to find a structural MRI biomarker. However, another possibility is that NAc volume differences may be obscured by variation in OCD subtypes, or that subcortical alterations in OCD may depend on gender (Zhang et al., 2019). Development of models that account for these subgroups requires a further increase in sample size.

Given that structural alterations in OCD patients are small, often finding limited effect sizes in large multicenter group studies (Bruin et al., 2020), inclusion of additional imaging modalities, such as (resting-state) functional and diffusion MRI, could strengthen the predictive value of our models (Van Waarde et al., 2015; Zhutovsky et al., 2019). The availability of functional and diffusion MRI scans for our cohort was limited, since most patients were routinely treated and not enrolled into a neuroimaging study. Conversely, structural MRI scans were readily available due to their necessity in surgical planning. Increased use of tractography in surgical planning for DBS for OCD will improve future availability of diffusion MRI scans (Baldermann et al., 2019; Coenen et al., 2017; Liebrand et al., 2019).

4.1. Limitations

The most notable limitation to this study is its sample size. Despite being among the largest studies on patients with DBS for psychiatric conditions, our sample was still modest for state-of-the-art machine learning applications. This could have caused our individual-level prediction to be underpowered. In addition, at these sample sizes it is impossible to stratify for differences in disease history, medication use, and OCD subtypes. Given the long timeframe during which this dataset was acquired, the only possibility of rapidly increasing the number of patients would be pooling data from different sites. However, pooling data across centers comes with its own set of challenges, like variation in diagnosis and inclusion criteria per institute, non-uniformity of stimulation targets and parameters across sites, and restrictions on data sharing due to privacy laws. These challenges might explain the lack of large retrospective multicenter studies in DBS for OCD.

Another limitation lies in the naturalistic follow-up for all patients after the first 16 patients. After the initial trial (Denys et al., 2010) DBS was approved for routine care for treatment-refractory OCD. Combined with the long inclusion period, this caused the treatment follow-up and imaging parameters to vary over time. To address this issue, we corrected for scanner/parameter combinations in our analyses. More importantly, after analysis of our clinical trial cohort showed that active contacts were always located in the vALIC (van den Munckhof et al., 2013), the targeting was altered so that the 3 topmost contacts were always placed in the vALIC white matter for new patients. This heterogeneity in targeting strategies potentially confounded our results, although given the large degree of overlap in anatomical positioning of the active contacts in our previous study on a subsample of this dataset (Liebrand et al., 2019) we expect no systematic differences between (non-)responders. The more important relationship between positioning of the electrodes and individual white matter connections is impossible to ascertain without additional diffusion MRI data. Comparisons over such a long timeframe could have been improved by using a fixed protocol. However, it is debatable whether this would have been beneficial for the patients. Patients should be able to benefit from new insights gained with experience. We attempted to address this limitation by including a covariate indicating the time since first operation into our model which showed that the association remained significant. However, it is important to note that changes in targeting cannot be assumed to vary linearly across patients and such an adjustment cannot circumvent the need for a fixed protocol.

The current study focused on response to DBS within a 12-month follow-up. This time period enables the identification of most responders, though a small minority only starts responding between one to two years after the application of DBS (van Westen et al., 2021). Therefore, future studies could investigate whether the observed associations also applies to patients with a delayed response.

4.2. Conclusions

We performed the – to our knowledge – largest neuroimaging study on patients who received DBS for treatment-refractory OCD. Our results showed that increased left-side NAc volume was associated with a lower 12-month follow-up Y-BOCS score. Caveted by non-significant

Table 3

|          | MAE         | MSE         | RMSE        | Pearson correlation | R²          |
|----------|-------------|-------------|-------------|---------------------|-------------|
| GM       | 9.23 (2.03) | 129.44 (47.16) | 11.19 (2.05) | -0.036 (0.012)     | -0.684 (0.572) |
| [5.37–13.85] | [50.35–247.44] | [2.05–15.73] | [-0.496–0.156] | [-2.556–0.156] |
| WM       | 9.07 (1.64) | 123.87 (44.80) | 10.97 (1.90) | 0.012 (0.246)      | 0.628 (0.568)  |
| [5.91–13.04] | [51.24–278.98] | [7.16–16.70] | [-0.309–0.253] | [-2.812–0.157] |
| GM + WM  | 8.80 (1.73) | 119.17 (40.90) | 10.77 (1.82) | 0.055 (0.247)      | 0.592 (0.655)  |
| NAc      | 7.84 (1.46) | 92.87 (32.02) | 9.50 (1.61) | 0.365 (0.272)      | 0.253 (0.514)  |
| [4.89–11.81] | [38.43–178.91] | [6.20–13.38] | [-0.208–0.738] | [-1.477–0.430] |
| ATR      | 9.02 (1.93) | 128.17 (53.55) | 11.11 (2.20) | 0.133 (0.279)      | -0.694 (0.686) |
| [5.44–16.01] | [54.08–329.40] | [7.35–18.15] | [-0.662–0.583] | [-1.910–0.205] |
| NAc + ATR| 9.17 (1.72) | 126.27 (43.82) | 11.07 (1.98) | 0.253 (0.340)      | -0.698 (0.672) |
| [4.43–13.57] | [33.90–237.21] | [5.82–15.40] | [-0.552–0.772] | [-2.443–0.471] |
| Scalar   | 8.96 (1.99) | 119.07 (58.20) | 10.69 (2.20) | 0.161 (0.293)      | 0.586 (0.829)  |
| [5.59–17.74] | [55.35–437.43] | [7.44–20.91] | [-0.585–0.719] | [-5.286–0.305] |

MAE: Mean absolute error; MSE: Mean squared error; RMSE: Root mean squared error; R²: Coefficient of determination; GM: Grey-matter volume; WM: White-matter volume; NAc: Grey-matter volume of Nucleus Accumbens; ATR: White-matter volume of Anterior Thalamic Radiation
predictions at the individual-level, group-level associations between NAc volume and DBS treatment outcomes suggest that patients with a larger NAc are better able to benefit from CBT and regain their function after receiving DBS. Although individual-level predictions with SVC/SVR were not predictive, the results could provide a stepping stone for future biomarker studies for DBS for OCD. It is our hope that these studies will contribute to improved informing and supporting of patients and clinicians in their decision-making process, which can help optimize the response rate, reduce potential harm or burden to patients, and improve the allocation of resources.

CRediT authorship contribution statement

Luka C. Liebrand: Conceptualization, Methodology, Formal analysis, Data curation, Writing - original draft. Paul Zhutovsky: Methodology, Software, Formal analysis, Writing - original draft. Eva K. Tolmeijer: Data curation. Ilse Graat: Data curation. Nienke Vulink: Investigation. Pelle de Koning: Investigation. Martijn Figee: Investigation. P. Richard Schuurman: Investigation. Pepijn van den Munckhof: Investigation. Mathian W.A. Caan: Supervision. Damiaan Denys: Funding acquisition. Guido A. van Wingen: Conceptualization, Supervision, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This study was supported by Netherlands Organization for Scientific Research (NWO/ZonMW Vidi 016.156.318), and an Innovation Impulse Grant (#2015.011) from the Academic Medical Center.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2021.102640.

References

Alberton, B.A.V., Nichols, T.E., Gamba, H.R., Winkler, A.M., 2020. Multiple testing corrections at the individual-level, group-level associations between NAc volume and DBS treatment outcomes suggest that patients with a larger NAc are better able to benefit from CBT and regain their function after receiving DBS. Although individual-level predictions with SVC/SVR were not predictive, the results could provide a stepping stone for future biomarker studies for DBS for OCD. It is our hope that these studies will contribute to improved informing and supporting of patients and clinicians in their decision-making process, which can help optimize the response rate, reduce potential harm or burden to patients, and improve the allocation of resources.

CRediT authorship contribution statement

Luka C. Liebrand: Conceptualization, Methodology, Formal analysis, Data curation, Writing - original draft. Paul Zhutovsky: Methodology, Software, Formal analysis, Writing - original draft. Eva K. Tolmeijer: Data curation. Ilse Graat: Data curation. Nienke Vulink: Investigation. Pelle de Koning: Investigation. Martijn Figee: Investigation. P. Richard Schuurman: Investigation. Pepijn van den Munckhof: Investigation. Mathian W.A. Caan: Supervision. Damiaan Denys: Funding acquisition. Guido A. van Wingen: Conceptualization, Supervision, Funding acquisition.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Acknowledgement

This study was supported by Netherlands Organization for Scientific Research (NWO/ZonMW Vidi 016.156.318), and an Innovation Impulse Grant (#2015.011) from the Academic Medical Center.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.nicl.2021.102640.

References

Alberton, B.A.V., Nichols, T.E., Gamba, H.R., Winkler, A.M., 2020. Multiple testing corrections at the individual-level, group-level associations between NAc volume and DBS treatment outcomes suggest that patients with a larger NAc are better able to benefit from CBT and regain their function after receiving DBS. Although individual-level predictions with SVC/SVR were not predictive, the results could provide a stepping stone for future biomarker studies for DBS for OCD. It is our hope that these studies will contribute to improved informing and supporting of patients and clinicians in their decision-making process, which can help optimize the response rate, reduce potential harm or burden to patients, and improve the allocation of resources.
NeuroPsychopharmacology 41 (5), 1395-1403. https://doi.org/10.1038/ npp.2015.292.
Figue, M., de Koning, P., Claassen, S., Vullink, N., Mantione, M., van den Munchkopf, P., Schuurman, R., van Wingen, G., van Amelsvoort, T., Bous, J., Denys, D., 2014. Deep Brain Stimulation Induces Striatal Dopamine Release in Obsessive-Compulsive Disorder. Biol Psychiatry 75 (8), 647–652. https://doi.org/10.1016/j. biopsych.2013.06.021.
Figue, M., Luigjes, J., Smolders, R., Valencia-Alfonso, C.E., van Wingen, G., de Kwaasteniet, B., Mantione, M., Ooms, P., van Koning, P., Vullink, N., Levar, N., Droge, L., van den Munchkopf, P., Schuurman, P.R., Nedererveen, A., van den Brink, W., Mazaheri, A., Vink, M., Denys, D., 2013. Deep brain stimulation restores frontal-striatal network activity in obsessive-compulsive disorder. Nat. Neurosci. 16 (4), 386–387. https://doi.org/10.1038/nn.3344.
Figue, M., Vink, M., de Geus, F., Vullink, N., Veltman, D.J., Westenberg, H., Denys, D., 2011. Dysfunctional Reward Circuitry in Obsessive-Compulsive Disorder. Biol Psychiatry 69 (9), 867-874. https://doi.org/10.1016/j.biopsych.2010.12.003.
Gan, J., Zhong, M., Fan, J., Liu, W., Niu, C., Cai, S., Zou, L., Wang, Y., Wang, Y., Tan, C., Chan, R.C.K., Zhu, X., 2017. Abnormal white matter structural connectivity in adults with obsessive-compulsive disorder. Transl Psychiatry 7 (3), e1062. https://doi.org/10.1038/tp.2017.22.
Günther, V., Imre, K., Kersting, A., Hoffmann, K.-T., Schuurman, R., van Wingen, G.A., 2015. A functional MRI marker may predict the outcome of deep brain stimulation in obsessive-compulsive disorder. Mol Psychiatry 20 (5), 609–614. https://doi.org/10.1038/mp.2014.78.
van Westen, M., Breetvelt, E., Bergfeld, I.O., Koning, P., Vullink, N., Ooms, P., Grant, I., Liebrand, I., Munchkopf, P., Schuurman, R., Denys, D., 2021. Optimizing Deep Brain Stimulation Parameters in Obsessive-Compulsive Disorder. Neuromodulation 24 (2), 307–315. https://doi.org/10.1111/nem.13524.
Winkler, A.M., Webster, M.A., Brooks, J.C., Tracey, I., Smith, S.M., Nichols, T.E., 2016. Threshold-free cluster enhancement: Addressing problems of smoothing, threshold dependence and localisation in cluster inference. Neuroimage 82, 83–98. https://doi.org/10.1016/j.neuroimage.2013.08.061.
Smolders, R., Mazaheri, A., van Wingen, G., Fige, M., de Koning, P.P., Denys, D., 2013. Deep Brain Stimulation Targeted at the Nucleus Accumbens Decreases the Potential for Pathologic Network Communication. Biol Psychiatry 74 (10), e27–e28. https://doi.org/10.1016/j.biopsych.2013.03.012.
Tierney, T.S., Abd-El-Barr, M.M., Stanford, A.D., Foote, K.D., Okun, M.S., 2014. Deep brain stimulation and ablation for obsessive compulsive disorder: evolution of contemporary indications, targets and techniques. Int. J. Neuropsychopharmacology 17 (4), 394–402. https://doi.org/10.1016/j.ijnp.2013.08.026.
van den Munchkopf, P., Bosch, D.A., Mantione, M.H.M., Fige, M., Denys, D.A.J.P., Schuurman, P.R., 2013. Active Stimulation Site of Nucleus Accumbens Deep Brain Stimulation in Obsessive-Compulsive Disorder Is Localized in the Ventral Internal Capsule. In: Nikkhah, G., Pinker, M. (Eds.), Stereotactic and Functional Neurosurgery. Springer Vienna, Vienna, pp. 53–59. https://doi.org/10.1007/978-3-7091-1482-7_9.
Van Laere, K., Nuttin, B., Gabriels, L., Dupont, P., Rasmussen, S., Greenberg, B.D., Coyn, S., 2006. Metabolic Imaging of Anterior Capsular Substitution in Refractory Obsessive-Compulsive Disorder: A Key Role for the Subgenual Anterior Cingulate and Ventral Striatum. J. Neurol. Med. 43, 740–747.
van Waarde, J.A., Scholte, H.S., van Oudheusden, L.J.B., Verwey, B., Denys, D., van Wingen, G.A., 2015. A functional MRI marker may predict the outcome of electroconvulsive therapy in severe and treatment-resistant depression. Mol. Psychiatry 20 (5), 609–614. https://doi.org/10.1038/mp.2014.78.
van Westen, M., Breetvelt, E., Bergfeld, I.O., Koning, P., Vullink, N., Ooms, P., Grant, I., Liebrand, I., Munchkopf, P., Schuurman, R., Denys, D., 2021. Optimizing Deep Brain Stimulation Parameters in Obsessive-Compulsive Disorder. Neuromodulation 24 (2), 307–315. 10.1111/nem.13524. https://doi.org/10.1111/11111111111.
Winkler, A.M., Webster, M.A., Brooks, J.C., Tracey, I., Smith, S.M., Nichols, T.E., 2016. Non-parametric combination and related permutation tests for neuroimaging. Hum Brain Mapp. 37 (4), 1486–1511. 10.1002/hbm.23115.
Wood, J., Alami, S.E., 2015. A Framework for Understanding the Emerging Role of Corticlimbic–Ventricral Striatal Networks in OCD-Associated Repetitive Behaviors. Front Syst Neurosci. 9, 171. https://doi.org/10.3389/fnsys.2015.00171.
Yun, J.-Y., Jang, J.H., Kim, S.N., Jung, W.H., Kwon, J.S., 2015. Neural Correlates of Response to Pharmacotherapy in Obsessive-Compulsive Disorder: Individualized Cortical Morphology-Based Structural Covariance. Prog Neuro-Psychopharmacol. Biol Psychiatry 63, 126–133. https://doi.org/10.1016/j.pnpbp.2015.06.009.
Zhang, L., Hu, X., Li, L., Lu, L., Li, B., Hu, X., Bu, X., Tang, S., Tang, W., Liu, N., Yang, Y., Gong, Q., Huang, X., 2019. Characteristic alteration of subcortical nuclei shape in medication-free patients with obsessive-compulsive disorder. NeuroImage Clin. 24, 102040. https://doi.org/10.1016/j.nicl.2019.102040.
Zhutovsky, P., Thomas, R.M., Oht, M., van Rooy, S.J.H., Kennis, M., van Wingen, G.A., Graat, I., 2019. Individual prediction of psychotherapy outcome in posttraumatic stress disorder using neuroimaging data. Transl Psychiatry 9 (1), 10.1038/s41398-019-0663-7.

8